Literature DB >> 2304250

[Reaction products of sevoflurane with components of sodalime under various conditions].

M Kudo1, T Kudo, T Oyama, A Matsuki.   

Abstract

Sevoflurane is reported to react with sodalime to resolve into several products. We examined the reaction products of sevoflurane when this anesthetic reacted with components of sodalime under various conditions. Analysis of reaction products was performed by gas chromatography using a 2m column packed with DOP. Six peaks including sevoflurane were detected on the gas chromatogram of sevoflurane after reaction with sodalime and five reaction products were obtained. These peaks were from P1 with the shortest retention time to P5 with the longest retention time. When sevoflurane was sealed with sodalime in a test tube at room temperature, only P1 was detected and all reaction products of P1 to P5 were identified when the test tube was heated at 50 degree C for 3 hours. Sodalime contains Ca (OH)2, NaOH, KOH and silicon dioxide. Reaction of sevoflurane with KOH produced P1 to P5 products even at room temperature. After the reaction of sevoflurane with NaOH or Ca (OH)2 at 50 degrees C, P1 to P5 or P1 only were detected on the chromatogram respectively. No peak of any reaction products was obtained after the reaction with silicon dioxide under various conditions. These results suggest that hydroxy group of sodalime component would increase reaction products of sevoflurane.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2304250

Source DB:  PubMed          Journal:  Masui        ISSN: 0021-4892


  2 in total

1.  Compound A concentration and the temperature of CO2 absorbents during low-flow sevoflurane anesthesia in surgical patients.

Authors:  M Osawa; T Shinomura; M Murakawa; K Mori
Journal:  J Anesth       Date:  1995-03       Impact factor: 2.078

Review 2.  Sevoflurane. A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia.

Authors:  S S Patel; K L Goa
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.